GD Travel Guide
Toursite (name/keyword)
eg: temple, park, golf,       mountain, resort . . . . . .
    Exchange Rate



   Home-Culture/Life/Edu-People And Life
People And Life
Culture News | People&Life | Education | Arts & Artists| GD Special
Anti-HIV drug set for clinical testing
Latest Updated by 2007-04-17 10:40:00

A new anti-HIV compound developed by Chinese scientists has been licensed for clinical testing on the mainland.

The drug, named Nifeviroc, looks set to become China's first entry-inhibitor for HIV treatment. It has been jointly developed by Pei Gang, a scientist at the Shanghai Life Sciences Institute, and Ma Dawei, a scientific researcher with the Shanghai Institute of Organic Chemistry. Both institutes come under the China Academy of Sciences.

Ma said that Nifeviroc works by inhibiting CCR5, a protein that commonly exists on the surface of human immune cells.

"The CCR5 protein provides a medium through which the HIV virus can infect healthy cells. By deactivating the protein, the virus can be stopped before it enters the cell," Ma said.

Early tests have indicated that Nifeviroc has promising anti-virus capabilities and few side effects. Hopes are therefore high that it can provide an effective barrier against the HIV virus.

The drug, which is taken orally, can be used on its own, or as part of a cocktail therapy.

The world's scientists first turned their attention to CCR5 in the mid-1990s.

An American company is currently involved in third-phase clinical testing of a drug with a similar mechanism to Nifeviroc, and this is expected to become the world's first oral HIV entry-inhibitor.

It will be a further three to five years before Nifeviroc is ready to be put into clinical use, the scientists said.

Pei and Ma have so far spent six years on the development of the drug. "It is perfectly normal for the development of a new drug to take 10 years or more," Ma said.

Chen Li, general manager of Target Pharmaceutical Co Ltd - co-founded by the two science institutes and Fudan Zhangjiang Bio-Pharmaceutical Co Ltd, said: "China generally lags behind the West when it comes to the development of pharmaceuticals, but Nifeviroc has an independent intellectual property.

"According to laboratory test results, its effects were just as good as those achieved by the American scientists."

Chen said Nifeviroc would also be cheaper than other drugs available. "The price will definitely be lower than foreign drugs," he said.

Ma said that a cooperation contract for the international marketing of Nifeviroc had recently been signed with an Australian firm.

"Chinese pharmaceutical companies do not have the experience to effectively market a drug like this on a global scale," Ma said.

"We are not familiar with the different regulations and laws each country has, and we also need help with funding.

"However, when the drug is introduced on to the market, we will be paid for the intellectual property rights and also get a percentage of the sales revenue," Ma said.

Editor: Wing

By:Zhang Kun Source:China Daily Website
- Relevant Stories -
HIV program to enlist help of gay community
Shenzhen plans methadone clinics to curb HIV
This site contains material from other media for content enrichment purpose only.
The website do not endorse such content and do not bear the joint responsibility of their copyright infringement.
The views expressed in written material posted to the bulletin boards of are those of the authors and/or publishers. The website does not endorse information products posted by organizations and individuals here. The originators of these information products are solely responsible for their content.
For copyright infringement issues, you shall contact within thirty (30) days. Email:
Home | News | Brief Business | PRD | Gov Info | Cities & Towns | Culture/Life/Edu | Travelling | Enjoy Life | Pictures | Specials
About Us | Contact Us |
© registered number 020074 | ICP Certificate No.B2-20050252
If you find any error in this page, please drag your mouse to mark the text with error, then press "CTRL" and "ENTER", to inform us. Thanks for your help!